We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+2.22%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$121M
AUM Growth
-$4.02M
Cap. Flow
-$6.69M
Cap. Flow %
-5.54%
Top 10 Hldgs %
48.15%
Holding
84
New
10
Increased
18
Reduced
47
Closed
7

Top Buys

Rank Stock Value
1
IQV icon
IQVIA
IQV
+$1.62M
2
GILD icon
Gilead Sciences
GILD
+$1.35M
3
INSM icon
Insmed
INSM
+$1.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$1.23M
5
MDT icon
Medtronic
MDT
+$1.06M

Top Sells

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$1.4M
2
AMGN icon
Amgen
AMGN
+$1.38M
3
ABBV icon
AbbVie
ABBV
+$1.02M
4
CTNM
Contineum Therapeutics
CTNM
+$982K
5
LLY icon
Eli Lilly
LLY
+$935K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
26
Bristol-Myers Squibb
BMY
$124B
$1.28M 1.06%
+21,150
New +$1.23M
UTHR icon
27
United Therapeutics
UTHR
$22.7B
$1.15M 0.95%
1,710
-13
-0.8% -$6.47K
VERA icon
28
Vera Therapeutics
VERA
$2.76B
$1.08M 0.9%
25,573
-11,285
-31% -$486K
RCUS icon
29
Arcus Biosciences
RCUS
$3.44B
$1.04M 0.86%
45,070
-11,875
-21% -$256K
ROIV icon
30
Roivant Sciences
ROIV
$24.8B
$1.02M 0.84%
32,500
-12,847
-28% -$330K
MDT icon
31
Medtronic
MDT
$106B
$962K 0.8%
+11,100
New +$1.06M
TRVI icon
32
Trevi Therapeutics
TRVI
$2.71B
$939K 0.78%
74,446
-9,809
-12% -$110K
COGT icon
33
Cogent Biosciences
COGT
$6.68B
$902K 0.75%
22,140
-10,545
-32% -$389K
MLYS icon
34
Mineralys Therapeutics
MLYS
$2.39B
$895K 0.74%
31,618
-7
-0% -$205
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$35.7B
$864K 0.72%
2,310
-680
-23% -$231K
TARS icon
36
Tarsus Pharmaceuticals
TARS
$2.61B
$852K 0.71%
11,272
-3,468
-24% -$242K
RAPP
37
Rapport Therapeutics
RAPP
$2.04B
$835K 0.69%
25,421
-13,504
-35% -$380K
NKTR icon
38
Nektar Therapeutics
NKTR
$2.31B
$821K 0.68%
10,851
-2,634
-20% -$150K
SNDX icon
39
Syndax Pharmaceuticals
SNDX
$2.02B
$787K 0.65%
31,680
-29,520
-48% -$641K
ARDX icon
40
Ardelyx
ARDX
$1.28B
$781K 0.65%
+122,394
New +$810K
PFE icon
41
Pfizer
PFE
$143B
$772K 0.64%
27,500
+350
+1% +$9.32K
BOLD
42
Boundless Bio
BOLD
$55.7M
$746K 0.62%
678,574
– –
ASND icon
43
Ascendis Pharma A/S
ASND
$17.1B
$728K 0.6%
2,800
-454
-14% -$102K
AVBP icon
44
ArriVent BioPharma
AVBP
$1.55B
$720K 0.6%
30,013
-8,242
-22% -$186K
GPCR icon
45
Structure Therapeutics
GPCR
$3.45B
$711K 0.59%
14,102
-9,770
-41% -$669K
IMTX icon
46
Immatics
IMTX
$1.31B
$693K 0.57%
66,830
+3,815
+6% +$37.4K
BBIO icon
47
BridgeBio Pharma
BBIO
$15.9B
$687K 0.57%
8,100
-3,070
-27% -$223K
SPRY icon
48
ARS Pharmaceuticals
SPRY
$695M
$677K 0.56%
79,150
+49,347
+166% +$473K
ONC
49
BeOne Medicines Ltd
ONC
$32.4B
$631K 0.52%
1,870
-795
-30% -$257K
TECX
50
Tectonic Therapeutic
TECX
$615M
$628K 0.52%
19,059
-23,196
-55% -$571K
1
2
3 4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CCM
Chicago Capital Management Chicago, Illinois $121M AUM 74.36% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
FWA
Fulcrum Wealth Advisors Bellevue, Washington $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM

Sectoral Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Sectoral Asset Management held 84 positions worth $121M, down 3.2% from $125M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sectoral Asset Management withdrew a net $6.69M in Q1 2026, closing 7 positions and reducing 47 holdings. Its most notable exit was AstraZeneca, an estimated $1.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in IQVIA worth $1.42M.

  • Sectoral Asset Management's largest Q1 2026 buy was IQVIA: 8,307 shares worth $1.42M.
  • Sectoral Asset Management added most to Gilead Sciences in Q1 2026, an estimated $1.35M increase.
  • Sectoral Asset Management's biggest Q1 2026 reduction was Amgen, cutting an estimated $1.38M.
  • Sectoral Asset Management fully exited AstraZeneca in Q1 2026, selling an estimated $1.4M.
  • Sectoral Asset Management's ten largest holdings make up 48% of its $121M portfolio in Q1 2026.
  • Sectoral Asset Management opened 10 new positions and closed 7 in Q1 2026.
  • Sectoral Asset Management's portfolio value fell 3.2% quarter-over-quarter to $121M.

Based on Sectoral Asset Management's 13F filing for Q1 2026, filed 15 May 2026.